FDA fast tracks Shire’s SHP626 nonalcoholic steatohepatitis drug
July 29, 2016Research and Development FDA, SHP626, Shire, liver fibrosis, nash, volixibat, volxibat
The Food and Drug Administration (FDA) has granted Fast Track designation to Shire’s SHP626 (volixibat) treatment for patients suffering from …
Bristol-Myers Squibb grows revenues 17% to $4.9 billion in Q2 2016
July 29, 2016Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, finance, opdivo
Bristol-Myers Squibb has announced its financial results for the second quarter of 2016, noting sizeable year-on-year sales growth and leaps …
China’s Fosun seals $1.3 billion deal for Gland Pharma
July 29, 2016Medical Communications, Sales and Marketing acquisition, fosun, gland, takeover
Fosun Pharmaceutical has agreed a deal to purchase an 86.1% stake of Gland Pharma, which will see the Chinese firm …
Ulcerative colitis treatment Xeljanz records positive top-line results in Phase III trial
July 29, 2016Medical Communications, Research and Development Pfizer, Xeljanz, tofacitinib, ulcerative colitis
Pfizer has announced positive top-line results from oral clinical trials for tofacitinib in ulcerative colitis (Octave) sustain, the third Phase …
Earnings drop at Sanofi as it looks for a quick Medivation resolution
July 29, 2016Medical Communications, Research and Development 2016, Medivation, Q2, Sanofi, earnings
Sanofi has published its earnings results for Q2, which show a fall in sales and profits as their diabetes division …
Roche urges reform of Cancer Drugs Fund as NICE takes control
July 29, 2016Medical Communications, Research and Development, Sales and Marketing CDF, Cancer Drugs Fund, NICE, Roche
Roche has warned that cancer patients in England are facing into an “uncertain future” as the new Cancer Drugs Fund …
Ashfield provides clarity on the age old debate: ‘Syndicated’ or ‘Dedicated’ field sales?
July 28, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Ashfield is understandably well placed to offer a balanced viewpoint on field sales teams. With over 20 years of experience, …
Strong early data on haemophilia gene therapy boosts Biomarin
July 28, 2016Medical Communications, Research and Development BioMarin, gene therapy, haemophilia a
Biomarin has presented interim results from a Phase I/II study that is being hailed as positive “proof-of-concept” data for their …
Cholesterol drugs drag AstraZeneca’s profits down in latest financial results
July 28, 2016Research and Development, Sales and Marketing 2016, AstraZeneca, Q2, h1, results
AstraZeneca has maintained its financial outlook for 2016, despite its Q2 and H1 results showing sharp falls in core earnings …
LMTX fails Phase III trial, monotherapy benefits seen
July 28, 2016Research and Development Alzheimer's, LMTX, TauRX, phase III, phase III failure
TauRX Therapeutics has reported Phase III clinical trial results for its novel tau aggregation inhibitor LMTX. The results indicated that …
Sanofi gets FDA approval for type-2 diabetes treatment Adlyxin
July 28, 2016Research and Development, Sales and Marketing FDA, Lixisenatide, Lyxumia, Sanofi, adlyxin, approval, diabetes, type 2, type-2, zealand
Sanofi has announced that the US Food and Drug Administration (FDA) has approved Adlyxin (lixisenatide), which is a once-daily mealtime …
John Lechleiter to step down as Lilly CEO
July 27, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eli Lilly, John Lechleiter
Eli Lilly has announced that CEO John Lechleiter is set to retire, with David Ricks to assume the role as …
Shire and BMS secure NICE recommendations for oncology drugs
July 27, 2016Research and Development, Sales and Marketing BMS, Baxalta, NICE, Oncaspar, Shire, Yervoy, opdivo
The National Institute for Health and Care Excellence (NICE) has issued final guidance recommending Shire’s Oncaspar (pegaspargase) and Bristol-Myers Squibb’s …
Orkambi deemed not suitable for NHS use
July 27, 2016Manufacturing and Production, Research and Development Orkambi, Vertex, Vertex Pharma, cystic fibrosis
The National Institute for Health and Care Excellence (NICE) has issued its recommendation that the cystic fibrosis drug Orkambi (lumacaftor/ivacaftor) …
Pharma unit helps boost profits at Bayer
July 27, 2016Research and Development, Sales and Marketing Bayer, Q2, results
The pharmaceutical division at Bayer was the driving force, as the company announced a 5.7% increase in second quarter profit …
Eli Lilly Q2 2016 results surpass estimates
July 27, 2016Research and Development, Sales and Marketing Eli Lilly, financial report
Eli Lilly has released its financial report for the second quarter of 2016, noting a number of promising results. The …
Failure in pivotal Phase III study obliterates stock at Tokai Pharmaceuticals
July 27, 2016Research and Development phase III, prostate cancer, tokai pharmaceuticals
Shares at Tokai Pharmaceuticals have been sent into freefall following the suspension of a pivotal Phase III trial for their …
GSK announces significant post-Brexit UK investment
July 27, 2016Manufacturing and Production, Research and Development GSK, UK, brexit, investment
GlaxoSmithKline has given the UK life sciences industry a major boost in the post-Brexit landscape with an announcement that £275 …
Innovate UK appoints first director of Health and Life Sciences
July 26, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Ian Campbell, Innovate UK, appointment, health and life sciences
Ian Campbell has been named by Innovate UK as its first director for Health and Life Sciences. Innovate UK is …
New drugs to utilise DNA damage response to kill cancer cells
July 26, 2016Research and Development, Sales and Marketing AstraZeneca, Cancer, Wellcome Trust, chemotherapy, dna damage response, university of sussex
The University of Sussex is set to produce a portfolio of new cancer drugs which exploit our DNA damage response …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
